The translational potential of these findings in AML are high, as both S55746 (NCT02920541) and the clinical MCL1 inhibitor derivative S64315 (NCT02979366) are both currently undergoing phase 1 clinical evaluation in human AML. This evidence concerns the gene MCL1 and acute myeloid leukemia.